New combo therapy aims to help PBC patients who Don't respond to standard treatment
NCT ID NCT05751967
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding fenofibrate to standard ursodeoxycholic acid (UDCA) therapy improves liver health in people with primary biliary cholangitis (PBC) who do not respond well to UDCA alone. About 150 adults will receive either the combination or a placebo plus UDCA for 36 weeks. The main goal is to see if more patients achieve normal levels of key liver markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fenofibrate combined with ursodeoxycholic acid
What this could lead to
If successful, this could offer a new treatment option for people with primary biliary cholangitis who do not get enough benefit from standard therapy alone.
What could go wrong
This is a Phase 3 trial, but it is still early to know if the combination works better than placebo. Results may not apply to all populations, and fenofibrate can have side effects like muscle pain or liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Provincial People's Hospital,
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Memorial Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The second hospital of Lanzhou University
RECRUITINGLanzhou, Gansu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ying han
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••